These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1218 related articles for article (PubMed ID: 11238504)

  • 1. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans.
    Di Vito L; Broglio F; Benso A; Gottero C; Prodam F; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Ghigo E; Arvat E
    Clin Endocrinol (Oxf); 2002 May; 56(5):643-8. PubMed ID: 12030916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans.
    Broglio F; Gottero C; Benso A; Prodam F; Casanueva FF; Dieguez C; van der Lely AJ; Deghenghi R; Arvat E; Ghigo E
    Clin Endocrinol (Oxf); 2003 Jan; 58(1):92-8. PubMed ID: 12519418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.
    Arvat E; Ramunni J; Giordano R; Maccagno B; Broglio F; Benso A; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1999 Jan; 22(1):23-8. PubMed ID: 10090133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Giordano R; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E
    Eur J Endocrinol; 2000 Nov; 143(5):601-6. PubMed ID: 11078983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
    Arvat E; Di Vito L; Lanfranco F; Broglio F; Giordano R; Benso A; Muccioli GP; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1999 Feb; 22(2):91-7. PubMed ID: 10195374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans.
    Arvat E; Di Vito L; Broglio F; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 2000 Sep; 23(8):493-5. PubMed ID: 11021763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans.
    Benso A; Prodam F; Lucatello B; Gramaglia E; Riganti F; Schneider H; van der Lely AJ; Muccioli G; Ghigo E; Broglio F
    Neuropeptides; 2007 Feb; 41(1):45-9. PubMed ID: 17112585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency.
    Aimaretti G; Baffoni C; Broglio F; Janssen JA; Corneli G; Deghenghi R; van der Lely AJ; Ghigo E; Arvat E
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):765-71. PubMed ID: 12072046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state.
    Broglio F; Gianotti L; Destefanis S; Fassino S; Abbate Daga G; Mondelli V; Lanfranco F; Gottero C; Gauna C; Hofland L; Van der Lely AJ; Ghigo E
    Clin Endocrinol (Oxf); 2004 May; 60(5):592-9. PubMed ID: 15104562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
    Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
    J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.
    Arvat E; Maccagno B; Ramunni J; Broglio F; Lanfranco F; Giordano R; Benso A; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1998 Nov; 21(10):673-9. PubMed ID: 9854683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
    Maccario M; Veldhuis JD; Broglio F; Vito LD; Arvat E; Deghenghi R; Ghigo E
    Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P; Isidro ML; Garcia-Buela J; Leal-Cerro A; Broglio F; Tassone F; Ghigo E; Dieguez C; Casanueva FF; Cordido F
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans.
    Hataya Y; Akamizu T; Takaya K; Kanamoto N; Ariyasu H; Saijo M; Moriyama K; Shimatsu A; Kojima M; Kangawa K; Nakao K
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4552. PubMed ID: 11549707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
    Grottoli S; Arvat E; Gauna C; Maccagno B; Ramunni J; Giordano R; Maccario M; Deghenghi R; Ghigo E
    Pituitary; 1999 Nov; 2(3):197-204. PubMed ID: 11081154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
    Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
    Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.